A phosphatidylinositol 3-Kinase/p70 ribosomal S6 protein kinase pathway is required for the regulation by insulin of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase gene expression in human muscle cells

J Biol Chem. 1999 Nov 26;274(48):34005-10. doi: 10.1074/jbc.274.48.34005.

Abstract

Insulin acutely up-regulates p85alpha phosphatidylinositol 3-kinase (p85alphaPI 3-K) mRNA levels in human skeletal muscle (Laville, M., Auboeuf, D., Khalfallah, Y., Vega, N., Riou, J. P., and Vidal, H. (1996) J. Clin. Invest. 98, 43-49). In the present work, we attempted to elucidate the mechanism of action of insulin in primary cultures of human muscle cells. Insulin (10(-7) M, 6 h of incubation) induced a 2-fold increase in p85alphaPI 3-K mRNA abundances (118 +/- 12 versus 233 +/- 35 amol/microgram total RNA, n = 5, p < 0.01) without changing the expression levels of insulin receptor, IRS-1, glycogen synthase, and Glut 4 mRNAs in differentiated myotubes from healthy subjects. The effect is most probably due to a transcriptional activation of the p85alphaPI 3-K gene because the half-life of the mRNA was not affected by insulin treatment (4.0 +/- 0.8 versus 3.1 +/- 0.4 h). PD98059 (50 microM) did not modify the insulin response but increased p85alphaPI 3-K mRNA levels in the absence of insulin, suggesting that the mitogen-activated protein kinase pathway exerts a negative effect on p85alphaPI 3-K mRNA expression in the absence of the hormone. On the other hand, the insulin effect was totally abolished by LY294002 (10 microM) and rapamycin (50 nM). In addition, overexpression of a constitutively active protein kinase B increased p85alphaPI 3-K mRNA levels. These results indicate that the phosphatidylinositol 3-kinase/PKB/p70S6 kinase pathway is required for the stimulation by insulin of p85alphaPI 3-K gene expression in human muscle cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cells, Cultured
  • Chromones / pharmacology
  • Dactinomycin / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Glycogen Synthase / genetics
  • Humans
  • Insulin / pharmacology*
  • Insulin Receptor Substrate Proteins
  • Middle Aged
  • Morpholines / pharmacology
  • Muscle, Skeletal / cytology
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / enzymology
  • Phosphatidylinositol 3-Kinases / genetics*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoproteins / genetics
  • Protein Serine-Threonine Kinases*
  • Protein Synthesis Inhibitors / pharmacology
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / physiology
  • Proto-Oncogene Proteins c-akt
  • RNA, Messenger / drug effects
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptor, Insulin / genetics
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / physiology
  • Regulatory Sequences, Nucleic Acid*
  • Ribosomal Protein S6 Kinases / genetics*
  • Ribosomal Protein S6 Kinases / metabolism
  • Signal Transduction
  • Sirolimus / pharmacology
  • Transcription, Genetic / drug effects

Substances

  • Chromones
  • Enzyme Inhibitors
  • Flavonoids
  • IRS1 protein, human
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Morpholines
  • Phosphoproteins
  • Protein Synthesis Inhibitors
  • Proto-Oncogene Proteins
  • RNA, Messenger
  • Recombinant Fusion Proteins
  • Dactinomycin
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Glycogen Synthase
  • Receptor, Insulin
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Sirolimus